“All member states of the WHO recognized the burden of psoriasis and […] that too many people in the world suffer needlessly from psoriasis due to incorrect or delayed diagnosis.” World Health Assembly 67.9, May 2014

PsorX – a breakthrough for inflammatory skin diseases

Psoriasis and atopic dermatitis or other forms of dermatitis are amongst the most common inflammatory diseases. However, up to 50 % of patients with psoriasis and eczema are misdiagnosed due to substantial overlap between both entities. Therefore, modern biologicals and small-molecule inhibitors tailored for either psoriasis or eczema fall short of their therapeutic potential.


Over a decade of research, we have succeeded in developing a two-gene classifier test which efficiently distinguishes psoriasis from all forms of eczema - even in cases where conventional diagnostic methods failed.

Our unrivalled test – PsorX differentiates between eczema and psoriasis on a molecular level with > 95% sensitivity and specificity.

Pipeline Products

From our biomarker pipeline, novel tests will address clinically relevant questions for comprehensive diagnostics in dermatology.

Our approach


As a team of leading researchers and clinicians in dermatology we are driven by moving diagnostic frontiers to achieve a breakthrough for patients with skin diseases. From our multi-omics data, we identify the most valuable biomarker combinations and translate them into easy-to-use high-tech diagnostic tools, addressing unmet clinical needs.


Myocosis fungoides

“The diagnosis of early MF (patch stage) is particularly challenging […] This diagnosis might be elusive because MF in its early stage shares clinical and histopathological features with inflammatory benign dermatoses…and immunohistochemistry and molecular analysis have limited utility as isolated criteria“ (Torres_Cabala, 2020)

Mycosis fungoides (MF) is a malignant tumor of the skin. Using conventional methods, MF can rarely be differentiated from inflammatory diseases such as eczema in the initial stage. Adjunct techniques such as T-cell clonality analysis are of limited advantage. However, correct and early diagnosis is mandatory to enable the affected patients a normal life expectancy. We develop a gene expression based molecular test to allow early diagnosis of MF and thus a significantly better prognosis.

Malignant melanoma

“Several promising biomarkers [in melanoma] show prognostic value [...], however, the scarcity of reliable data precludes the use of these biomarkers in current clinical applications” (Ding et al., 2022)

Malignant melanoma is the most prevalent cause of death among dermatological diseases. In the last decade, targeted therapies have been developed that require companion diagnostics, namely identification of driver mutations. We develop a mutation and gene expression-based test offering unparalleled value for diagnosis and prognosis of melanoma.